Subscribe To
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annual...
October 14, 2023, 8:30 pm
Bitcoin price prediction as btc bounces from recent bottom – is a trend reversal near?
Bitcoin, the flagship cryptocurrency, seems to be showing signs of resilience. After its recent price plummet, BTC has managed to bounce off from its ...
October 14, 2023, 7:14 pm
Black diamond therapeutics presents dose escalation data demonstrating durable responses in patients with nsclc from phase 1 trial of bdtx-1535
Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across hete...
October 14, 2023, 4:30 pm
Coherus announces toripalimab data at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 ...
October 14, 2023, 4:30 pm
Mid-october 2023 watchlist: leading ancillary cannabis stocks
The cannabis industry's landscape is still changing at an incredibly fast rate as we approach mid-October 2023. The ancillary business has become a ho...
October 14, 2023, 3:00 pm
Billy joel, sting to perform together for first time at tampa show
Music icons and have announced a one night only performance at Raymond James Stadium in Tampa, Florida, on February 24, 2024. Read Full Story The post...
October 14, 2023, 3:00 pm
Ai stocks avgo and anet lead 5 resilient names near buy points
AI stocks Broadcom and Arista lead five names near buy points all sporting a flat base, showing resilience in a tough market....
October 14, 2023, 10:44 am
Triplepoint venture: this 15.8% yield may be too risky
TriplePoint Venture Growth saw a surge in problematic loans in its portfolio in Q1'23 and Q2'23, which could lead to a dividend cut going forward. The...
October 14, 2023, 8:54 am
Main street capital: capture a 7.1% yield that has demonstrated strong results recently (rating upgrade)
Main Street Capital offers a yield of nearly 7.1%, beating interest rates in a challenging market. The company has shown improved performance, with hi...
October 14, 2023, 6:45 am
1 investing method that shows why this warren buffett stock is a must-buy
Bottom-up investing focuses on the company itself rather than macroeconomic factors. The adoption of digital payments has worked wonders for Visa's fi...
October 14, 2023, 6:22 am
Simon property group: 7.1% yield is not enough
Simon Property Group is the largest owner of shopping malls in the US, but there are better alternatives in the REIT retail segment. The company's rev...
October 14, 2023, 6:08 am
Week ahead – us retail sales and earnings, major chinese data, and uk inflation and employment readings
US This week Wall Street will learn how quickly the US consumer is weakening and if the manufacturing part of the economy is close to entering recover...
October 14, 2023, 2:06 am
Xrp news: sec vs. ripple showdown set for 2024; settlement hopes in the hands of coinbase
Following the Court’s ruling, XRP’s inclusion in global crypto products increases after SEC’s motion for an interlocutory appeal got denied. The...
October 14, 2023, 1:38 am